Selank and Semax are lab-made peptides, each containing seven amino acids. Selank is based on tuftsin, a small immune peptide. Semax is based on a fragment of the hormone ACTH.
Selank is often called an anti-anxiety peptide and Semax a focus or memory peptide. Human research only partly supports that distinction. The direct comparison found for this article measured brain connectivity on scans, without testing anxiety, memory or attention.
Selank and Semax at a glance
| Feature | Selank | Semax |
|---|---|---|
| What it is | Seven-amino-acid peptide: tuftsin (an immune peptide) plus Pro-Gly-Pro | Seven-amino-acid peptide: a four-amino-acid piece of the hormone ACTH plus Pro-Gly-Pro |
| Main research areas | Anxiety in patients; attention and memory alongside anxiety; immune and gene studies in animals | Stroke recovery; BDNF and learning in animals; brain scans in healthy volunteers |
| Human evidence | Small studies against or with benzodiazepines, several with attention and memory tests; one small uncontrolled cognitive pilot | One 16-person task study with mixed results; a stroke study of daily function and a blood marker; brain-imaging studies |
| Direct comparison | One brain-imaging study in healthy adults; no anxiety, memory or attention outcomes | Same study (Semax 14, Selank 16, placebo 22) |
| Major limitations | Small, short, open-label or uncontrolled designs; maker funding; conflicting records for one trial | Very small task study; stroke study design unclear; imaging without behavioral outcomes, with maker-supplied product |
| Regulatory status | Not an FDA-approved drug | Not an FDA-approved drug |
Where each peptide comes from
Both peptides were developed within a Russian research network that included the Institute of Molecular Genetics of the Russian Academy of Sciences and Moscow State University. Researchers from that network wrote most of the studies below. Peptogen, the Russian company that makes both peptides, funded or supplied several studies.
The shared tail is proline, glycine and proline (Pro-Gly-Pro). The developers described it as a way to slow the peptide’s breakdown in the body. The first four amino acids differ:
Selank: tuftsin, a peptide linked to immune cells.
Semax: a piece of ACTH, a pituitary hormone. It does not contain the rest of the hormone.
Some suppliers sell modified versions, such as N-acetyl Semax or forms with an amide group added. These are different molecules. No human studies of these versions were found for this article, so findings for the original peptides cannot be assumed to apply.
What lab and animal research suggests
Researchers have proposed several ways these peptides might work. Most of the evidence comes from cells, brain tissue and rodents.
In a study of rat brain membranes, Selank changed how GABA, a calming brain chemical, bound to its receptors. The authors proposed this as one possible route for its anti-anxiety effects. Other rodent studies reported changes in serotonin activity and in genes tied to inflammation.
Animal research on Semax has centered on BDNF, a protein that supports the growth and survival of nerve cells. In a rat study, a single treatment raised BDNF in the hippocampus, a brain area involved in memory, and the rats performed more learned avoidance responses.
The human studies below did not directly test these proposed mechanisms. One Semax stroke study measured BDNF in blood, which does not establish its level in the brain.
Human studies of Selank
The human Selank studies reviewed here were small and conducted in Russia. Most compared it with a benzodiazepine, a class of anti-anxiety drugs. Several also tested attention and memory.
Selank compared with medazepam
In a study in patients with anxiety, 62 people with generalized anxiety disorder or neurasthenia (a diagnosis involving fatigue and nervous exhaustion) received either Selank or medazepam, a benzodiazepine.
The researchers reported that both drugs reduced anxiety scores by a comparable amount and that Selank also eased fatigue. Side effects were reported more often with medazepam.
Comparable scores in a small study do not show that the two drugs work equally well. The published records also disagree about how many patients received each drug, and the available text does not describe how patients were assigned or whether anyone was blinded.
Selank compared with phenazepam
In a 14-day study of 60 patients with anxiety disorders, including some whose anxiety showed up as physical symptoms, patients were randomly assigned to Selank or phenazepam, another benzodiazepine. Both patients and doctors knew which drug was given.
Phenazepam reduced anxiety more during treatment. By day 14, scores on the anxiety scale had fallen about 55 percent with phenazepam and about 26 percent with Selank.
Researchers counted patients as responding if their total score on an anxiety and depression scale fell by at least half. At day 14, 5 Selank patients and 7 phenazepam patients met that mark. A week after treatment stopped, the counts were 17 and 9.
During that week, average anxiety scores rose again with phenazepam but continued falling with Selank. The authors interpreted this as a longer-lasting Selank effect.
The study also used two thinking tests:
The Stroop test, which measures attention and the ability to ignore distracting information.
A verbal fluency test, which counts how many words a person can produce in a set time.
Stroop results stayed near their starting level with Selank. Verbal fluency showed a small upward trend that was not statistically significant. Both tests worsened with phenazepam.
These results suggest Selank preserved test performance compared with phenazepam; they do not show an improvement with Selank.
Side effects were far more common with phenazepam. A few Selank patients reported attention or memory problems, longer sleep or nasal dryness. The Selank group had only 30 people, followed for three weeks, so this cannot establish long-term safety.
Peptogen and a Russian government science fund paid for the study.
Selank added to phenazepam
A follow-up study by the same team randomly assigned 70 patients to phenazepam alone (30) or phenazepam plus Selank (40). The authors reported fewer phenazepam side effects, including attention and memory problems, when Selank was added. Peptogen and the same science fund paid for this study too.
The phenazepam-alone figures match those in the earlier study. The papers may share a comparison group, though neither confirms this.
A small pilot study of attention and memory
A 2010 pilot study tested Selank in 15 adults aged 54 to 76 with mild cognitive complaints linked to blood-vessel disease of the brain. Patients first took a placebo for a week, and anyone who improved on placebo was dropped before Selank began.
After two weeks on Selank, scores improved significantly on a rating of concentration and short-term memory and on simple reaction time. A computer test of short-term visual memory showed only a trend toward improvement.
There was no comparison group during the Selank phase. The small, selected sample and repeated testing make it hard to separate a drug effect from practice or other changes over time. Four patients had trouble sleeping or brief restlessness in the first week.
Human studies of Semax
The Semax studies reviewed here include a small task study in shift workers, a stroke study and brain scans of healthy volunteers.
The power-plant operator study
A 1996 English-language report included a study of 16 male power-plant operators. Eight were randomly chosen to receive Semax and eight received a placebo, and neither the operators nor the researchers knew who got which.
On two working days, the operators memorized number images and pressed a key when a matching number appeared. The task was scored three ways:
Correct responses: pressing the key for a matching number.
Wrong responses: pressing the key for a number that did not match.
False responses: pressing the key when no number was shown at all.
Compared with the first morning, correct responses at the end of the first shift fell to 47 percent in the placebo group and 91 percent in the Semax group. Wrong responses rose in the placebo group and fell in the Semax group.
False responses showed a different pattern. On the first evening, they fell more with placebo than with Semax. On the second day, they rose in the Semax group. The authors suggested anxiety might explain this, but they did not measure anxiety.
The paper did not report side effects. With eight people per group and one task, it offers little evidence about benefits outside that setting.
Stroke recovery
In a study of 110 patients after ischemic stroke, patients in early and late rehabilitation groups either received Semax or did not. The researchers measured a blood level of BDNF, muscle strength and the Barthel index, a scale of independence in daily tasks such as dressing and walking.
Patients who received Semax had higher BDNF levels and better Barthel scores, with less effect on weakness. The English abstract does not say how patients were assigned to Semax or whether anyone was blinded.
These findings concern physical recovery after stroke. The study did not test memory or attention.
Brain scans of healthy volunteers
In a brain-imaging study of 24 healthy adults, 14 received Semax and 10 received a placebo. Scans taken at rest showed that one front portion of a brain network that is active when the mind is not focused on a task covered a larger area in the Semax group.
The scan showed a difference in how much area the network covered. This does not mean the brain grew or became more active overall. The study reported no thinking or mood tests.
Direct comparison of brain activity
A brain-imaging comparison is the only study found in this review that gave Selank and Semax to people in the same experiment. Peptogen supplied the peptides.
Researchers randomly assigned 52 healthy adults to Semax (14 people), Selank (16) or a placebo (22) and scanned them before and 5 and 20 minutes after a single dose. They looked at how well regions linked to anxiety and to working memory stayed in sync with the rest of the brain.
The groups differed in one link, between the right amygdala, a region involved in fear, and part of the right temporal lobe. Between the 5- and 20-minute scans, the link strengthened in both peptide groups compared with placebo. In the first five minutes, it weakened in the Semax group compared with placebo, while the Selank group showed no significant difference from placebo.
The Selank and Semax groups already differed on that connection before treatment, which the authors attributed to chance in small groups. With no anxiety, memory or attention tests, the study cannot show which peptide works better for those outcomes.
The Semax group here was the same size as in the team’s earlier Semax scan study. Neither paper says whether participants overlapped.

Is it accurate to say Selank is for anxiety and Semax is for focus?
Only partly. Selank has mostly been studied in anxious patients, while Semax has been studied in other settings. No study found for this article compared them on anxiety or focus.
Selank research also includes attention and memory tests. Performance generally held steady compared with phenazepam, while one small pilot without a comparison group reported gains. The Semax studies reviewed did not measure anxiety. Its evidence on thinking rests on one small task study with mixed results.
These labels describe the research areas more clearly than they describe proven differences in effects.
What about Selank and Semax blends?
Selank and Semax are sold together in blends, but no published human study of the combination was found for this article.
The FDA review of Semax documented products containing both peptides. A premixed blend contains both in one product. Other accounts describe using two separate products together.
Some forum users report using the two together for sharper focus or clearer thinking alongside less anxiety or stress. Experiences vary, and personal accounts cannot establish whether the combination works, is safe or produces typical results.
The brain-imaging comparison above tested Selank, Semax and placebo in separate groups. It did not test a blend. Findings for either peptide alone do not establish what happens when they are combined.
Safety reporting
Safety information comes mostly from small, short studies. Many reports do not discuss side effects, which does not mean none occurred.
Studies comparing Selank with benzodiazepines recorded fewer side effects with Selank. That finding covers only a few weeks and cannot establish long-term safety.
For Semax, an FDA review prepared for an advisory committee found no published human case reports of adverse events. Its search of FDA’s adverse event database identified one consumer report of eye pain and burning, with a hospital stay, after use of a Semax product bought online. A single report like this cannot show that Semax caused the problem, confirm what the product contained, or say how often such reactions happen.
The FDA review also found that most studies it examined did not discuss adverse events and identified no standard animal toxicity studies. No long-term human safety studies of either peptide were found for this article.
Regulatory status
Neither Selank nor Semax is an FDA-approved drug.
Both have been nominated as ingredients for pharmacy compounding in the United States, which is a separate process from drug approval. FDA’s list of compounding ingredients that may present significant safety risks names both among nominations that were withdrawn. For each, FDA said there may be a risk of immune reactions for certain routes of use, because of possible clumping of the peptide and peptide-related impurities, and that safety information is limited or lacking.
An FDA advisory committee has also reviewed Semax as a possible compounding ingredient. That process does not make it an FDA-approved drug.
Some suppliers sell both peptides labeled “research use only.” That is a product label, not an FDA category or approval.
What the comparison establishes
Selank has mostly been studied in anxious patients, including tests of attention and memory. Semax research covers stroke recovery, a small task study and brain scans. Those different research histories do not establish which peptide is better for anxiety or focus.
The direct comparison measured brain connectivity. Questions about symptom relief, thinking and long-term safety remain unresolved for both peptides and for their combination.
